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Abstract The adipocyte-derived cytokine leptin acts as a
metabolic switch, connecting the body’s metabolism to
high-energy consuming processes such as reproduction and
immune responses. We here provide genetic and bio-
chemical evidence that the metabolic and immune
functions of leptin can be uncoupled at the receptor level.
First, homozygous mutant fatt/fatt mice carry a spontane-
ous splice mutation causing deletion of the leptin receptor
(LR) immunoglobulin-like domain (IGD) in all LR iso-
forms. These mice are hyperphagic and morbidly obese,
but display only minimal changes in size and cellularity of
the thymus, and cellular immune responses are unaffected.
These animals also displayed liver damage in response to
concavalin A comparable to wild-type and heterozygous
littermates. Second, treatment of healthy mice with a
neutralizing nanobody targeting IGD induced weight gain
and hyperinsulinaemia, but completely failed to block
development of experimentally induced autoimmune dis-
eases. These data indicate that leptin receptor deficiency or
antagonism profoundly affects metabolism, with little
concomitant effects on immune functions.
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SEAP Secreted alkaline phosphatase
STAT Signal transducer and activator of transcription
TNF-a Tumour necrosis factor alpha
TReg Regulatory T cell
Introduction
Leptin, the 16 kDa adipocyte hormone product of the ob
gene, influences a multitude of biological processes,
including immunity [1], reproduction [2], linear growth [3],
glucose homeostasis [4] and bone metabolism [5]. How-
ever, it is best known for its dramatic effect as a satiety
signal, since mouse strains deficient in leptin signalling are
hyperphagic and obese [6]. Primarily produced in adipo-
cytes, leptin provides information about the availability of
energy stores and functions predominantly, but not exclu-
sively, at the level of the mediobasal hypothalamus to
modulate feeding and energy expenditure, thus regulating
body weight. Adequate leptin signalling appears to be
permissive for energy expensive processes such as linear
growth, reproduction and adequate immune responses, all
of which are dysregulated when the leptin signalling
pathways are compromised.
Leptin plays a role in both innate and adaptive immunity
(reviewed in [1]) and leptin deficiency causes immune
dysfunction and increased risk of infection in mice and
man [7, 8]. In innate immunity, it promotes secretion of
inflammatory cytokines and the activation of macrophages,
neutrophils and natural killer cells. Functions in adaptive
immunity include thymic homeostasis, naı¨ve CD4? cell
proliferation and promotion of T helper 1 (TH1) responses.
In addition, leptin suppresses the expansion of
CD4?CD25high regulatory T cells (TRegs) that dampen
immune reactions [9]. Leptin’s role in CD4? T cell-med-
iated responses links the hormone to the onset and
progression of several T cell-controlled autoimmune dis-
eases, including Crohn’s disease [10], rheumatoid arthritis
[11], multiple sclerosis [12, 13] and autoimmune hepatitis
[14–16].
Six LR isoforms (LRa-f) with an identical extracellular
domain are produced by alternative splicing or ectodomain
shedding: one long, four short and one extracellular soluble
variant. The LR long form (LRlo or LRb) is the only
variant capable of efficient signalling and is highly
expressed in certain nuclei of the hypothalamus [17], a
region of the brain involved in the regulation of body
weight. A 106 nucleotide insertion precisely at the junction
where the long and short form transcripts diverge in the lr
gene results in premature termination of the LRlo intra-
cellular domain and concomitant loss of hypothalamic
signalling, thus explaining the obese phenotype of db/db
mice [18]. Functional LRlo expression is also observed in
several peripheral cell types, including cells of the immune
system [17]. In line with this, PET imaging revealed sig-
nificant leptin binding to immune and hematopoietic cell
types [19].
LR is a member of the class I cytokine receptor
family [20]. Its ectodomain is composed of two cytokine
receptor homology (CRH1 and CRH2) domains, which
are separated by an immunoglobulin-like domain (IGD)
and followed by two membrane-proximal fibronectin
type III (FN III) domains. The CRH2 domain is neces-
sary and sufficient for leptin binding [21, 22], but
receptor clustering requires interaction with IGD as
leptin mutants that fail to contact this domain behave as
leptin antagonists [23]. Like all class I cytokine recep-
tors, the LR lacks intrinsic kinase activity and relies for
signalling on constitutively associated JAK2, a member
of the Janus tyrosine kinase family [24]. LR clustering
results in JAK2 transphosphorylation and activation of
several intracellular signalling cascades including the
STAT, MAPK, PI3 K and mTOR pathways (reviewed in
[25]).
In this study, we provide the first genetic and bio-
chemical evidence that different leptin-driven biological
processes can be uncoupled at the ligand/receptor interac-
tion level.
Materials and methods
Reagents
Mouse leptin was produced and purified as described ear-
lier [26] and 4.10-mAlb by the VIB Protein Service Facility
up to 95 % purity. LPS contaminations were less than 1 EU
per mg protein. LPS content was measured using the lim-
ulus amebocyte lysate in combination with a chromogenic
substrate (Cambrex), or with the Toll-like receptor 4
expressing Hek293-BlueTM cells (InvivoGen) according
to the manufacturer’s instructions. Antibodies Alexafluor
labelled anti-CD4 and PE labelled anti-CD8 (both from
eBiosciences) were used according to the manufacturer’s
instructions.
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Animals
FATT experiments: Mice used were of the 129/SvEvTac
strain and kindly provided by Dr Nancy Jenkins at the
National Cancer Institute-Frederick, Maryland, USA. The
obese phenotype arose during establishment of the colony
at the Walter and Eliza Hall Institute, Melbourne, Austra-
lia. Mice had ad libitum access to standard lab chow and
water and were on a 12-h light–dark cycle with lights-on at
07:00. Approval for the work described was granted by the
Howard Florey Institute Animal Ethics Committee (AEC)
and Monash University School of Biological Sciences
AEC. Mice of approximately 10 weeks of age were used
for the phenotypic characterization. For further experi-
ments (thymus and spleen characterization and the Con A
experiments), mice were backcrossed onto the C57BL/6
genetic background for at least 8 generations. Nanobody
experiments: C57BL/6 and DBA/1 mice were purchased
from Harlan Netherlands and Janvier, respectively. Ani-
mals were treated and used in agreement with the
institutional guidelines.
Sequencing and transcript analysis
Genomic DNA was isolated from tail tips using Proteinase K
(Sigma) with isopropanol purification. Hypothalamic tissue
was dissected from mouse brains, and RNA was extracted
using the RNeasy lipid tissue Mini-kitTM (Qiagen). Reverse
transcription was performed on 200 ng mRNA using
Superscript IIITM (Invitrogen). Oligonucleotide primers for
PCR and direct sequencing were designed using the Primer 3
program and PCR was performed under standard conditions
using TaqGold (Roche). PCR products were purified using
Magnesil Paramagnetic Particles (Promega), and DNA
sequencing was performed on an ABI 377 DNA sequencing
machine using Big Dye terminator chemistry.
Phenotypic studies
Blood was collected between 09:00 and 11:00 by retro-
orbital bleed from conscious, non-fasting animals. Glucose
was tested immediately on whole blood using an ‘‘Accu-
Chek Advantage’’ glucometer. Tissues were taken from
animals killed with an ip lethal injection of pentobarbital
sodium (Lethobarb, 100 mg/kg, Virbac). Mice were
weighed and measured from snout to anus along the ventral
surface before undergoing dissection and tissue collection.
Organs and fat pads were collected and weighed.
ConA induced hepatitis
Hepatitis was induced by an intravenous injection of indi-
cated amounts Con A (Applichem) dissolved in pyrogen-
free PBS. At different times after injection, blood was col-
lected and serum prepared. Serum alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) levels were
measured using a standard photometric method.
Collagen-induced arthritis (CIA)
Chicken type-II (CII) collagen (MB Biosciences) was
dissolved in 0.1 M acetic acid and emulsified with
complete Freund’s adjuvant (CFA) (incomplete Freund’s
adjuvant (sigma) ? Mycobacterium tuberculosis (Difco)).
100 ll of this emulsion was injected subcutaneously at
the base of the tail of DBA/1 mice. Twenty-one days
later, the animals were challenged with a second injection
of CII emulsified in incomplete Freund’s adjuvant. Mice
were treated ip with 4.10-mAlb (100 lg/mouse/day) or
PBS starting at day 20. Clinical severity of arthritis was
graded as follows: 0: normal paws; 0.5: erythema and
edema of one digit; 1: erythema and slight edema of the
tarsus or one joint; 2: erythema and moderate edema of
the tarsus or more than 1 joint; 3: erythema and severe
edema involving the entire paw; 4: ankylosis and defor-
mation. Scoring was performed by an investigator
unaware of the mouse identity. The arthritic score for
each mouse was obtained as the sum of the score
recorded for each limb individually.
Induction and assessment of experimental autoimmune
encephalomyelitis (EAE)
Male mice, 10–15 weeks of age, received subcutaneous
injection of 200 lg MOG35–55 peptide (Sigma) in 200 ll
sterile PBS emulsified with an equal volume of complete
Freund’s adjuvant (Sigma) containing 5 mg/ml Myco-
bacterium tuberculosis H37Ra (BD Biosciences). Mice
also received ip 50 ng pertussis toxin (Sigma) in 200 ll
sterile PBS, at the time of immunization and 48 h later.
Starting at day 7, mice were injected daily with PBS of
4.10-mAlb (100 lg/mouse/day). Animals were weighed
and clinically scored blindly on a daily basis: Clinical
signs of disease were scored as follows: 0: normal; 1:
weakness of the tail; 2: complete loss of tail tonicity; 3:
partial hind limb paralysis; 4: complete hind limb
paralysis; 5: forelimb paralysis or moribund; 6: death.
0.5 points were added for immediate clinical findings.
Thymocytes and splenocytes cultures
Mice were killed by cervical dislocation and organs dis-
sected. Lymphocytes were isolated by mincing and passing
through a nylon cell strainer (BD Falcon). Red blood cells
were lysed for 15 min in ACK (ammonium–chloride–
potassium) lysis buffer. Cell subpopulations were counted
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and analysed by 2-colour flow cytometry using a FAC-
Scalibur (Becton–Dickinson) with the appropriate FITC- or
PE-conjugated mAbs (see above).
Following splenocyte isolation, 6 9 105 cells were
cultured in 200 ll DMEM supplemented with 10 % FCS,
1 % glutamine and 1 % Penicillin/Streptamycin in de
presence of Con A (as indicated). Cells were plated into
96-well culture plates (Cellstar, Greiner Bio-One) and after
96 h of culture, supernatant was collected for cytokine
detection.
A
B
C
Fig. 1 Properties and effect of the FATT mutation in vivo. a Weekly
body weights of male mice in ‘‘C’’ generation (grandparental offspring
of a cross between A1 and A3). Results are shown as the mean
(±STDEV). Mice were grouped as ‘‘normal’’ or obese at 12 weeks of
age (normal n = 5, obese n = 4). b LR and LR-FATT alternatively
spliced transcripts. Sequence differences suggest the existence of two
alternatively spliced transcripts: LR-FATT1 (a 291-bp deletion
corresponding to the entire coding region of exon 7) and LR-FATT2
(retains 152 bp of intron 7 sequence between exons 7 and 8).
c Putative LR-FATT proteins compared to wild-type and LR db
receptors. The wild-type full-length receptor (LRb) contains all
described domains of the leptin receptor. The IGD main is excised
from LR-FATT1, while LR-FATT2 is truncated just after this domain.
The LR db receptor is truncated after box 1. CRH cytokine receptor
homology, IGD immunoglobulin-like, FN III fibronectin type III,
Y tyrosine
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Cytokine and SOL LR profiling
Serum COMP (AnaMar Medical), mouse IL-18 (MBL),
mouse insulin (Mercodia), mouse IFN-c, mouse TNF-a,
mouse IL-4 (all R&D systems) and (total) mouse leptin
(R&D Systems) were determined using ELISA’s according
to the manufacturer’s instructions. Free leptin levels were
quantified by coating Maxisorp plates (Costar) overnight
with mLREC purified protein (2 lg/ml in coating buffer
(50 mM NaCO3; pH 10,6)). After blocking, plates were
incubated with serum of treated mice. Leptin was detected
with a polyclonal secondary anti-leptin Ab and streptavi-
din-HRP (R&D Systems).
SOL LR levels were determined as follows: a 1,000-fold
dilution of mouse serum, or a serial dilution purified
mLREC as a standard, was allowed to bind to penta-His Ab
(Qiagen) coated Maxisorp plates (Costar). After washing,
plates were incubated for 2 h at room temperature with a
1/50 dilution of a COS-1 conditioned medium containing
the leptin-SEAP chimera (final concentration ±10 ng/ml).
Bound secreted alkaline phosphatase activity was mea-
sured using the chemiluminescent CSPD substrate
(PhosphaLight, Tropix) in a TopCount chemiluminescence
counter.
Construction of LR-FATT1
The expression plasmid pMET7 LR-FATT1 was con-
structed by introducing a Nhe I site just before and just
after the Ig-like domain coding sequence in the pMET7 LR
plasmid using site-directed mutagenesis (Stratagene). The
resulting vector was Nhe I cut and circularized.
Cell lines and transfection procedures
Hek293T, Hek293-BlueTM cells (InvivoGen) and MCF7
cells were cultured in 10 % CO2 humidified atmosphere at
37 C and grown using DMEM with 4,500 mg/l glucose,
10 % foetal bovine serum and 50 lg/ml gentamicin (all
from Invitrogen). Hek293T cells were transfected using a
standard calcium phosphate precipitation procedure [22].
Reporter assay, leptin binding assay and western blot
analysis
Reporter assay: Hek293T cells were transiently co-trans-
fected with the appropriate receptors and the STAT3
responsive pXP2d2-rPAP1 (rat pancreatitis associated
protein 1)-luciferase reporter [27]. Transfected cells were
stimulated overnight as indicated. Luciferase activity was
measured for 5 s in a TopCount chemiluminescence
counter (Packard).
Leptin binding properties of LR variants: leptin binding
was measured in a binding assay with a mouse leptin-
SEAP chimeric protein as described earlier [23]. In brief,
transfected Hek293T cells were incubated with a 1/50
dilution leptin-SEAP conditioned medium (see above).
Cells were washed and bound secreted alkaline phospha-
tase activity was measured using the chemiluminescent
CSPD substrate (PhosphaLight, Tropix) in a TopCount
chemiluminescence counter.
Western blot For STAT3 and JAK2 phosphorylation,
transfected Hek293T cells were serum-starved overnight
and stimulated for 15 min with ligand. Phosphorylated and
total protein levels were detected with, respectively, anti-
phospho STAT3 (Tyr705), anti-STAT3 (both from Cell
Signalling), or anti-phospho JAK2 (Tyr 1007/1008), anti-
JAK2 (both from Upstate Biotechnology) using standard
western blot techniques. To detect JAK2 phosphorylation
and expression, 0.01 lg pRK5-JAK2 was co-transfected.
Statistical analysis
Anatomical and blood measurements were analysed based
on genotype and sex. Statistical analyses were conducted
using two-way ANOVA in SPSS 15 (SPSS, Australia).
When significant effects or interactions were evident, post
hoc comparisons were performed using Tukey’s HSD test
when Levene’s test for homogeneity of variance was sat-
isfied and Games–Howell test when it was not. For
analyses of two groups, Mann–Whitney U tests were per-
formed. *P \ 0.05 and **P \ 0.001. SPSS and GraphPad
software was used for statistical data analysis.
Results
Obese fatt/fatt mice carry a leptin receptor lacking
the IGD
The obese fatt/fatt phenotype was first noticed when a rapid
post-weaning weight gain was observed in a proportion (12
out of 58 animals) of progeny arising from two indepen-
dent brother–sister matings of the same sibship in
129/SvEvTac mice. By 25 weeks of age, obese fatt/fatt
mice, without any sex bias, generally reached 75 g,
approximately three times the average adult weight of
wild-type animals (Fig. 1a). We concluded that the obese
phenotype was an autosomal recessive monogenetic trait.
A candidate gene approach was employed to identify the
fatt mutation, with the leptin and leptin receptor genes
sequenced in the first instance. No mutations were
observed in the leptin gene; however, in the LR coding
gene a guanine to adenosine nucleotide substitution (1,279
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G [ A) was observed that segregated precisely with the
obese phenotype. This 1,279 G [ A base substitution
affected the most 30 protein-coding nucleotide in exon 7
(encoding the IGD in the receptor), adjacent to the GT
splice donor of intron 7. RT-PCR analysis and sequencing
on mRNA isolated from the hypothalamus showed that two
new transcripts were generated in the obese mice. In the
first transcript, exon 7 had been excised precisely from the
transcript, juxtaposing exons 6 and 8. This splice variant
(minus exon 7) will hereafter be referred to as LR-FATT1.
The second RT-PCR product retained exon 7, but also the
entire 152 bp sequence of intron 7. This alternatively
spliced form of the LR transcript (plus intron 7) will
hereafter be referred to as LR-FATT2 (Fig. 1b). The pre-
dicted protein translation products of these alternate
transcripts are indicated in Fig. 1c.
In vitro properties of the LR variant lacking the IGD
FACS analysis was used to demonstrate that LR-FATT1 is
expressed on the membrane upon transfection (Fig. 2a).
Leptin-binding properties of wild-type LR and LR-FATT1
were compared using a leptin-SEAP (secreted alkaline
phosphatase) binding assay on transiently transfected
Hek293T cells. As shown in Fig. 2b, no differences were
observed, thus ruling out effects of deletion of the IGD on
ligand binding and cell-surface exposure. However, LR-
FATT1 was completely defective in generating a STAT3-
dependent signal as measured using a STAT3 responsive
luciferase reporter construct (Fig. 2c). Western blot ana-
lysis of JAK2 and STAT3 phosphorylation demonstrated
that the LR deletion variant was unable (up to leptin con-
centrations of 500 lg/ml) to stimulate JAK2 kinase activity
and hence to initiate downstream STAT3 signalling
(Fig. 2d).
Phenotypic analysis of the fatt/fatt mice
Phenotypic characterization of the obese animals was
conducted in 10- to 11-week-old homozygous obese mice
(fatt/fatt) and compared to age-matched wild-type and
heterozygous (fatt/?) mice. Briefly, fatt/fatt mice showed
significant increases in body weight, the weight of fat pads
and increased levels insulin (over tenfold compared to wild
type), blood glucose and leptin (Table 1). The fatt/fatt mice
had a longer body than wild-type and fatt/? mice (males
13 %, females 20 % longer compared to wild type). Fatt/
fatt mice of both sexes were infertile. Upon inspection, the
reproductive tract of the female appeared poorly developed
and fatt/fatt testes were small compared to non-obese males
(Supplementary Fig. S1).
Intriguingly, the thymus was increased in size and
weight in 10-week-old fatt/fatt mice and the spleen
appeared to be normal compared to age-matched wild-type
controls (Table 2). Furthermore, the total number of thy-
mocytes and splenocytes were comparable in wild-type,
heterozygous and obese mice (Fig. 3a, b). We did not
observe differences in the relative percentages in CD4 and
CD8 double positive, CD4?, CD8? and double negative
populations in both thymus and spleen (Fig. 3a, b). Finally,
splenocytes derived from fatt/fatt mice produced interferon
gamma (INF-c) in response to concanavalin A (Con A)
comparable to cells from wild-type or heterozygous ani-
mals (Fig. 3c). Taken together, fatt/fatt mice represent the
first case of LR deficiency with an intact immune
compartment.
LR deficiency does not suppress Con A induced
hepatitis
To assess the importance of a signalling competent LR in
immune responses in vivo, we compared obese fatt/fatt
and db/db mice with wild-type and heterozygous litter-
mates in the Con A mouse model for autoimmune
hepatitis. In two series of experiments, animals were
either treated according to their weight (i.e. 10 g/kg Con
A; Fig. 3d, e), or with a fixed dose (i.e. 400 lg Con A per
mouse; Fig. 3f, g). Blood ALT and AST levels were
measured 24 h after treatment. Neither the homozygous
LR fatt nor the db mutation resulted in a protection
against Con A induced hepatoxicity (Fig. 3d–f). Liver
enzymes were even significantly increased in some set-
ups. Wild-type and fatt/? animals reacted comparably to
Con A. Together, these data show that LR deficiency
results in the aggravation of an experimentally induced
autoimmune disease.
Administration of a nanobody targeting the IGD results
in weight gain and hyperinsulinaemia
Given the unexpected phenotype of fatt/fatt mice, we chose
to test the neutralizing, IGD-specific 4.10 nanobody [28] in
more detail in vivo. The nanobody was fused to a second
nanobody that binds mouse serum albumin (4.10-mAlb) to
prolong its half-life in circulation. This bispecific nanobody
clearly blocked LR STAT3 dependent signalling without
affecting the related LIF (leukaemia inhibitory factor)
receptor activation (Fig. 4a).
4.10-mAlb, the monospecific nanobody mAlb or PBS
was administered daily to 9- to 10-week-old C57BL/6 mice
for 14 days and metabolic parameters were scored. Fig-
ure 4b clearly illustrates that 4.10-mAlb provoked a
significant increase in body weight, accompanied by
enlargement of abdominal fat pad mass and hyperinsuli-
naemia (Fig. 4c, d). Together, these data demonstrate that
634 L. Zabeau et al.
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4.10-mAlb is a potent inhibitor of leptin’s metabolic
functions in vivo.
Targeting the IGD does not suppress experimentally
induced autoimmune diseases
To investigate whether the IGD is required for leptin’s
immuno-modulatory functions, 4.10-mAlb was evaluated
in three mouse models for autoimmune diseases: EAE, CIA
and Con A-induced hepatitis.
In C57BL/6 J mice, EAE was provoked by adminis-
tration of the MOG peptide (MOG35–55). Seven days
after this immunization, animals were treated on a daily
basis with 4.10-mAlb (100 lg/mouse/day) or PBS as a
negative control and clinically scored as described in the
‘‘Materials and methods’’. As shown in Fig. 5a, no sta-
tistically significant difference was observed between
4.10-mAlb- and PBS-treated mice as both followed a
typical disease course and developed signs of severe
paralysis, with an incidence of 100 % and reaching a
A B
C D
Fig. 2 Expression, binding and signalling properties of LR-FATT1.
a Hek293T cells were transiently transfected with plasmids encoding
the full-length LR, LR-FATT1 or empty vector (MOCK). LR
expression was monitored with FACS using mLR-specific antibodies.
b LR, LR-FATT1 or MOCK transfected Hek293T cells were
incubated with a serial dilution leptin-SEAP containing supernatants
as indicated. Cells were washed and bound alkaline phosphatase
activities measured. Mean values of quadruplicate measurements
(±STDEV) are plotted. c Hek293T cells transfected with receptors
and the STAT3-responsive rPAP1-luciferase reporter, were
stimulated overnight with a serial dilution of leptin. Data points are
the mean (±STDEV) of triplicate luciferase measurements. d Similar
transfections were performed to check for phosphorylation of JAK2
and STAT3. Serum-starved cells were stimulated with indicated
concentrations of leptin for 10 min or were left unstimulated. Lysates
were blotted onto a nitrocellulose membrane and analysed using
phospho-specific antibodies. Total amounts of JAK2 and STAT3 are
also shown. All datasets are representative for three independent
transfection experiments
Leptin’s metabolic and immune functions 635
123
mean maximal clinical score of 4.17 ± 0.067 (PBS) and
3.83 ± 0.21 (4.10-mAlb).
CIA was induced in DBA/1 mice by two (day 0 and 21)
challenges with chicken type-II collagen. One group was
treated semi-therapeutically (starting at day 20) with 4.10-
mAlb, while PBS-injected mice served as a control. Body
weight and clinical symptoms of arthritis were monitored
daily until day 42 after the first immunization. Despite a
Table 1 Phenotype data for wild-type (?/?), heterozygous (fatt/?) and obese (fatt/fatt) FATT mice at 10–11 weeks of age
Sex Males Females
Genotype ?/? fatt/? fatt/fatt ?/? fatt/? fatt/fatt
N 5 8 8 6 7 4
Body weight (g) 23.23 ± 2.68 23.39 ± 3.08 46.28 ± 3.86**## 16.63 ± 1.07 18.60 ± 2.16 38.92 ± 2.80**##
Body length (cm) 8.23 ± 0.74 8.28 ± 0.33 9.27 ± 0.27**## 7.28 ± 0.18 7.41 ± 0.59 8.70 ± 0.43**##
Femur length (mm) 15.00 ± 0.71 14.94 ± 0.62 14.42 ± 0.20 13.75 ± 0.69 13.86 ± 0.85 13.50 ± 0.50
Femur (mg) 35.93 ± 7.14 34.95 ± 6.00 36.45 ± 1.83 27.57 ± 5.64 27.63 ± 3.85 29.24 ± 2.83
Liver (mg) 905.50 ± 158.74 905.80 ± 123.58 1,551.70 ± 251.42**## 589.30 ± 55.61 694.60 ± 83.44* 1,068.80 ± 96.52**##
Liver (mg/body
weight)
38.80 ± 2.95 39.10 ± 5.97 33.60 ± 5.81 35.60 ± 4.85 37.4 ± 2.55 27.70 ± 3.89**##
Gonadal WAT (%
of body weight)
1.47 ± 0.10 1.86 ± 0.41 5.83 ± 0.77**## 2.04 ± 0.68 3.46 ± 1.19* 11.56 ± 0.53**##
Retroperitoneal
WAT (% of body
weight)
0.28 ± 0.06 0.34 ± 0.08 2.38 ± 0.25**##G 0.25 ± 0.07 0.42 ± 0.16 1.66 ± 0.31**##G
Subcutaneous
WAT (% of body
weight)
0.99 ± 0.31 1.09 ± 0.14 4.80 ± 0.64**##G 1.7 ± 0.52 2.24 ± 0.86 5.43 ± 0.28**##
Visceral WAT (%
of body weight)
2.10 ± 0.3 2.01 ± 0.38 3.85 ± 0.72**## 1.96 ± 0.39 2.26 ± 0.25 3.42 ± 0.33**##
BAT(% of body
weight)
0.36 ± 0.08 0.35 ± 0.05 0.74 ± 0.25**## 0.34 ± 0.09 0.40 ± 0.050 0.75 ± 0.16**##
Glucose (mM) 5.25 ± 1.66 5.79 ± 1.03 12.50 ± 3.40**##G 4.03 ± 0.97 4.89 ± 0.60 4.72 ± 1.18
Insulin (ng/ml) 0.79 ± 0.23 0.71 ± 0.47 73.10 ± 24.95**##G 0.31 ± 0.21 0.58 ± 0.31 26.91 ± 12.71**##G
Leptin (ng/ml) 7.10 ± 5.28 7.92 ± 6.51 116.36 ± 29.72**## 5.82 ± 3.60 7.98 ± 3.71 103.65 ± 25.51**##G
Age (days) 74.50 ± 3.0 75.80 ± 3.74 75.83 ± 2.86 72.17 ± 1.60 73.14 ± 3.24 73.00 ± 4.00
Results are displayed as average ± standard deviation
WAT white adipose tissue, BAT brown adipose tissue
Tukey’s HSD test used in all analysis unless noted, Games–Howell test (G): significance is denoted as * P \ 0.05 versus ?/?, ** P \ 0.001
versus ?/?, # P \ 0.05 versus fatt/?, ## P \ 0.0.001 versus fatt/?. Differences are not significant unless noted
Table 2 Spleen and thymus characteristics wild-type (?/?), heterozygous (fatt/?) and obese (fatt/fatt) mice $
Sex Males Females
Genotype ?/? fatt/? fatt/fatt ?/? fatt/? fatt/fatt
N 5 8 8 6 7 4
Spleen (mg) 132.13 ± 26.98 152.5 ± 33.91 149.20 ± 57.13 99.77 ± 17.46 113.51 ± 22.26 125.72 ± 43.77
Spleen (mg/body weight) 5.73 ± 1.25 6.54 ± 1.37 3.26 ± 1.37*## 6.05 ± 1.24 6.20 ± 1.53 3.26 ± 1.20**##
Thymus (mg) 46.30 ± 9.8 38.18 ± 14.38 67.12 ± 18.43## 42.60 ± 4.8 42.94 ± 8.92 68.04 ± 17.27**##
Thymus (mg/body weight) 2.03 ± 0.37 1.62 ± 0.76 1.37 ± 0.43 2.45 ± 0.33 2.15 ± 0.27 1.63 ± 0.52**#G
Age (days) 74.50 ± 3.0 75.80 ± 3.74 75.83 ± 2.86 72.17 ± 1.60 73.14 ± 3.24 73.00 ± 4.00
Results are displayed as average ± standard deviation
WAT white adipose tissue, BAT brown adipose tissue
Tukey’s HSD test used in all analysis unless noted, Games–Howell test (G): significance is denoted as * P \ 0.05 versus ?/?, ** P \ 0.001
versus ?/?, # P \ 0.05 versus fatt/?, ## P \ 0.001 versus fatt/?. Differences are not significant unless noted
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clear effect on body weight (data not shown), no protection
was observed in clinical arthritic scores (Fig. 5b). On the
contrary, a tendency towards aggravation of the disease
was seen in 4.10-mAlb-treated mice. The latter finding was
consistent with a significant increase in serum levels of
cartilage oligomeric matrix protein (COMP), a marker for
cartilage damage (Fig. 5c).
4.10-mAlb was also tested in the Con A mouse model
for autoimmune hepatitis. 4.10-mAlb or PBS as a negative
control was administered daily in C57BL/6 mice for
1 week. On day 7, Con A was injected intravenously and
blood was collected at 0 and 9 h. Serum ALT and AST
levels were significantly elevated in 4.10-mAlb-treated
mice (Fig. 6a). The increase in hepatic injury coincided
with a significant increase in tumour necrosis factor-alpha
(TNF-a) and trend towards elevated serum interleukin-18
(IL-18) concentrations (Fig. 6b). Together with the EAE
and CIA experiments, these results clearly illustrate that
4.10-mAlb is unable to block leptin’s immune-modulatory
functions in all three disease models.
Targeting the IGD induces hyperleptinaemia
and a concomitantly increased TH1 profile
Since leptin can modulate TH responses [29], we isolated
and cultured splenocytes from 4.10-mAlb- or PBS-treated
mice and measured interferon-gamma (IFN-c; a typical
TH1 cytokine) and IL-4 (a typical TH2 cytokine) levels
96 h after stimulation with Con A (Fig. 7a). A significant
increase in TH1 cytokine production was seen in 4.10-
mAlb-treated mice, in line with the worsening of arthritis
and hepatitis parameters. The effect on TH2 cytokine
secretion was only marginal. To understand the paradoxical
finding that a leptin antagonist can provoke an enhanced
TH1 response, we measured circulating leptin levels in
4.10-mAlb-treated animals. Data shown in Fig. 7b dem-
onstrate that 1-day or 1-week treatment resulted in a seven
and tenfold increase in serum leptin, respectively. Since no
effect on fat composition (and associated enhanced leptin
secretion) can be expected after 24 h, this strongly sug-
gested a direct effect on circulating leptin. Since the
soluble LR (SOL LR) is able to stabilize leptin in circu-
lation, SOL LR serum levels were measured after 1- or
7-day treatments. Data in Fig. 7c show an increase in both
cases, thereby providing an explanation for an enhanced
leptin serum half-life. To rule out that accumulation of
SOL LR decreased the bioavailability of free leptin, we
measured total and free leptin levels in a plate-binding
assay using, respectively, an anti-leptin Ab or the LR
ectodomain (see ‘‘Materials and methods’’ for details).
Results in Fig. 7d illustrate that 4.10-mAlb treatment
resulted in a clear increase in both total and free leptin
levels in a dose-dependent manner. This increase in
biologically active leptin levels provides an explanation for
the aggravation upon 4.10-mAlb treatment of the hepatic
damage in the Con A model.
Discussion
In this study we describe the characterization of a new
obese fatt/fatt mouse strain. The phenotype is caused by a
single base mutation close to the border of exon 7 in the LR
coding gene. This results in two new splice variants: one
lacking exactly the IGD encoding exon 7 (in all LR iso-
forms) and one including intron 7 (Fig. 1b). Both resulting
receptors LR-FATT1 (a membrane anchored form lacking
the IGD) and LR-FATT2 (a soluble variant) are signalling
deficient (Fig. 2c).
Like ob/ob (leptin deficient) and db/db (deficient in the
LR long form) mice, fatt/fatt mice are not only massively
obese, but also hyperinsulinemic, hyperglycemic (although
more pronounced in male animals) and hyperleptinemic
(Table 1) and infertile. The poor development of the
female reproductive tract and the smaller testes in male
fatt/fatt mice explains the infertility of the animals (Sup-
plementary Fig. 1). In agreement with observations in ob/
ob [30] and db/db [31] animals, fatt/fatt mice have an
increased vertebral length, supporting the role of leptin in
bone formation. In strong contrast to ob/ob mice [32], db/
db mice [33–35] or even fa/fa rats [36], the size and cel-
lularity of the spleen and thymus of fatt/fatt mice do not
seem to be different (or is even significantly bigger in the
case of the thymus) from heterozygous or wild-type ani-
mals (Table 2; Fig. 3). The relative percentages of CD4
and CD8 double positive CD4?CD8?, CD4?CD8-,
CD4-CD8? and double negative CD4-CD8- thymocytes
were similar in fatt/fatt, fatt/? and wild-type animals
(Fig. 3a, b), which was also observed in db/db mice [34].
Leptin deficiency, however, results in a marked decrease in
double positive cells, while single positive and especially
double negative cell numbers were significantly increased
[32]. Finally, the homozygous fatt mutation did not result
in altered INF-c secretion by splenocytes (Fig. 3c).
To the best of our knowledge, this is the first report of a
LR deficiency model in which the immune compartment
appears to be maintained. To further investigate this, fatt/
fatt mice were compared to wild-type and heterozygous
littermates in the Con A-induced hepatitis model. Sur-
prisingly, enzyme ALT and AST levels were significantly
increased upon treatment with fixed doses of Con A or
according to the animal’s weight (Fig. 3d–g). Also, we did
not observe a protection of db/db mice in this mouse model
(Fig. 3). The in vivo effects of the IGD-specific 4.10
neutralizing nanobody are completely in line with the
observations in fatt/fatt mice. Treatment of mice with the
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bispecific 4.10-mAlb nanobody induces a significant
increase in body weight and associated hyperinsulinaemia
(Fig. 4), but failed to improve the clinical outcome of the
CIA, EAE and ConA models for autoimmune diseases
(Figs. 5, 6).
In our Con A experiments, LR deficiency (fatt or db
mutation) or LR antagonism (4.10-mAlb) not only did not
result in protection, but even aggravated the disease
severity in some experimental set-ups. This may be
explained by the substantial increase in circulating leptin in
fatt/fatt, db/db or nanobody-treated animals. In the case of
nanobody treatment, this increase is likely not only due to
the increase in body fat but also a consequence of 4.10-
mAlb-mediated stabilization of the SOL LR (Fig. 7). This
bispecific nanobody is designed to tether 4.10 to albumin
and thus will capture the SOL LR, thereby preventing its
removal from circulation. Since 4.10 does not interfere
with leptin binding, this may enhance leptin’s serum half-
life. Indeed, not only the total but also the free leptin levels
appear to be increased since the majority of leptin in serum
is still able to bind the receptor in a plate binding assay
(Fig. 7d). This mechanism of induced hyperleptinaemia is
reminiscent of that found in Zucker Diabetic Fatty (ZDF)
rats and liver-specific insulin receptor knock-out (LIRKO)
mice, or as a consequence of over-expression of the SOL
LR [37, 38]. This SOL LR stabilizing effect might also
help to explain why the increase in body weight upon 4.10-
mAlb treatment is only modest (less than 10 % of the
initial body weight).
Our results appear contradictory to previous studies in
db/db mice and indicate that leptin and LRlo deficiency
affect immunity differently. Ob/ob mice are protected from
immune-mediated inflammation in various disease models,
such as experimental colitis [39], EAE [12, 13], Con
A-induced hepatitis [14–16], or antigen-induced arthritis
(AIA) [11]. Db/db mice develop a milder form of AIA
[11], dextran sulphate sodium (DSS) or Con A-induced
hepatitis [40]. To exclude the possibility that the experi-
mental set-up causes our contradictory results, we treated
animals either based on their weight, or with a fixed
amount of Con A. In both cases, fatt/fatt and db/db mice
reacted more to Con A than wild-type or heterozygous
animals.
One could argue that leptin’s immune signalling in db/
db mice is mediated, at least in part, by the LR short iso-
forms. Expression and functionality of these variants are
not affected by the db mutation [41]. Although these short
receptors lack cytoplasmic tyrosine residues and the so-
called box 2 motif necessary for JAK2 activation [42, 43],
they appear capable of signalling in certain experimental
set-ups [44, 45]. This is, however, unlikely since the fatt
mutation also results in the deletion of the IGD in these
variants and since the short forms should also be sensitive
to neutralization by the IGD-specific nanobody.
In line with our results, Palmer and colleagues were
the first to postulate that the effects of LRlo deficiency on
the immune system might be indirect and mediated by
changes in the environment [34]. They showed that bone
marrow cell transplants from db/db or wild-type mice to
wild-type recipients resulted in similar size and cellularity
of the thymus, as well as cellular and humoral immune
responses. In contrast, wild-type to db/db grafts greatly
affected the thymus fate. Also, macrophage infiltration of
adipose tissue in a peritoneal dialysis mouse model was
increased in db/db mice compared to wild-type littermates
[46]. The authors suggested that this is mainly caused by
the associated hyperleptinemia and that signalling occurs
via the LR short form. Finally, a neutralizing (both
binding of leptin and signalling) nanobody directed
against the CRH2 domain in the LR also worsened the
clinical outcome of Con A-induced hepatitis [47]. The
authors suggest that leptin protects against T cell-medi-
ated hepatitis via modulation of invariant natural killer
(iNKT).
Differences in leptin versus LR deficiency were also
observed in humans. In 2007, Farooqi and colleagues
sequenced the lr gene in 300 subjects with hyperphagia and
severe early-onset obesity [48]. This has led to the identi-
fication of five nonsense and four missense mutations that
resulted in the ablation of leptin signalling. Several phe-
notypic features seen in subjects with LR deficiency are not
as severe as those in subjects with leptin deficiency [49].
Three studies in patients illustrate that mutations in the
leptin or LR genes do not affect metabolic and peripheral
functions in the same way. A homozygous transition in the
leptin-coding gene resulting in a L72S replacement in the
leptin protein was identified in a 14-year-old child of non-
obese Austrian parents. The mutation does not affect
expression, but interferes with the secretion of the
bFig. 3 FATT mutation does not affect cellularity of the thymus and
spleen and aggravates Con A-induced hepatitis. Thymic (a) and
splenic (b) lymphocytes were isolated from 9- to 10-week-old wild-
type (?/?), heterozygote (fatt/?) and obese (fatt/fatt) mice. Cells
were counted and stained for CD4 and CD8 expression using FACS.
Bars represent averages ± SEM. c Splenocytes were seeded in
96-well plates and stimulated with indicated amounts of Con A for
96 h. IFN-c levels were determined in a specific ELISA. Bars
represent averages of 4 mice; quadruplicate values per mouse and
error bars the SEM. d–g Hepatitis in ?/?, fatt/? , fatt/fatt, or LR
deficient db/db and ?/? littermates mice was induced by intravenous
injection of Con A. Animals were treated either according to their
weight (10 mg/kg; d and e) or with a fixed amount Con A (400 lg;
f and g). Blood was collected at 0 and 24 h and serum ALT (d, f) and
AST (e, g) levels are plotted as averages (n = 10) ±SEM. Data are
representative for three or more experiments. Statistics: *P \ 0.05;
Mann–Whitney U test
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hormone. The child showed signs of a hypogonadotropic
hypogonadism, but only mild obesity and a normal T cell
responsiveness [50]. Nizard and colleagues reported the
pregnancy of a morbidly obese patient with a rare homo-
zygous LR mutation [51]. The child’s growth and
development have been normal. More recently, in
A
B
C D
Fig. 4 A nanobody targeting the LR IGD blocks leptin signalling
in vitro and induces weight gain upon administration. a LR and
rPAP1-luciferase reporter co-transfected cells were stimulated over-
night with sub-optimal leptin or LIF concentrations in the presence of
a serial dilution 4.10-mAlb. Luciferase activity was measured and
plotted as average (±STDEV) of triplicate measurements. b Body
weight changes of C57BL/6 mice injected daily with bispecific
nanobody (40 lg/day/mouse; n = 10), the monovalent mAlb (also
40 lg/day/mouse; n = 10) or PBS (n = 8) were followed for
14 days. Data are expressed as averages ±SEM. Results are
representative for at least four experiments. c Abdominal fat pad
weights were measured in mice treated for 7 days with 4.10-mAlb
(150 lg/mouse/day; n = 7) or PBS (n = 7) and plotted as averages
(±SEM). d Serum insulin levels in PBS or 4.10-mAlb-treated mice
(same as c) were measured as described in the ‘‘Materials and
methods’’. Error bars represent SEM. Data are representative for two
experiments. Statistics: *P \ 0.05, **P \ 0.001, Mann–Whitney
U test
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collaboration with Rogaev and co-workers, we character-
ised a genetic defect with a high incidence of early-onset
morbid obesity, but with limited effects on immunity and
fertility (Moliaka et al. in preparation).
In conclusion, we here provide genetic and biochemical
evidence that LR deficiency (fatt/fatt and db/db mice) or
LR antagonism (4.10-mAlb) has profound metabolic
effects, but does not interfere with immune responses. Our
study warrants caution for the use of LR-based antagonists
(antibodies or nanobodies) in autoimmune diseases and
certain cancers. However, the possibility to uncouple lep-
tin’s metabolic and immune functions opens the potential
bFig. 5 4.10-mAlb does not protect against experimental autoimmune
encephalomyelitis (EAE) and collagen-induced arthritis (CIA).
a EAE was induced in male C57BL/6 mice, and clinical symptoms
were scored in PBS (n = 6) or 4.10-mAlb (100 lg/mouse/day;
n = 7) treated mice after immunization with MOG35–55 peptide.
Average clinical scores are plotted ± SEM. b Arthritis was induced
in 9- to10-week-old DBA/1 mice with chicken type-II collagen on
days 0 and 21. Starting at day 20, mice were daily injected with 4.10-
mAlb (100 lg/mouse/day; n = 16) or PBS (n = 16). Average
clinical scores are plotted ± SEM. c On day 42, blood was collected
and COMP serum levels determined. Bars represent average (n = 16)
±SEM. Results are representative for two independent experiments.
Statistics: *P \ 0.05 and **P \ 0.001 Mann–Whitney U test
A
B
Fig. 6 4.10-mAlb worsens the clinical outcome of ConA-induced
hepatitis. a C57BL/6 mice were treated daily with 4.10-mAlb
(150 lg/mouse/day; n = 15) or PBS (n = 15) for 1 week. On day
7, 300 lg ConA was injected intravenous and blood collected at 0 and
9 h. Serum ALT and AST are plotted as averages ± SEM. Results are
representative of four independent experiments. b Serum IL-18 and
TNF-a levels in these PBS and 4.10-mAlb-treated mice were
measured and plotted as average ± SEM. Statistics: *P \ 0.05 and
**P \ 0.001 Mann–Whitney U test
A
B
C
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for the design of selective leptin or LR antagonists
(reviewed in [52]) that interfere with leptin’s peripheral
functions without affecting central weight regulation.
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